Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.
Please read the tutorial at this link. https://ebooknice.com/page/post?id=faq
We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.
For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.
EbookNice Team
Status:
Available4.8
15 reviewsMetastasis remains a significant challenge in the management of clear cell renal cell carcinoma (ccRCC), and a continued focus onits underlying mechanisms is crucial for improving patient outcomes and optimizing clinical therapies. The ovarian-tumor relatedprotease (OTU) is involved in regulating critical cell signaling pathways, but the functions of most OTUs have yet to be explored. Inthis study, an unbiased RNAi screening revealed that ovarian tumor domain-containing 2 (YOD1) knockdown significantlypromoted cell metastasis. YOD1 downregulation promoted ccRCC growth and metastasis both in vitro and in vivo. Notably, YOD1knockdown stimulated the growth of organoids derived from ccRCC patients. Further investigation revealed that YOD1 directlyinteracted with and stabilized Zinc finger protein 24 (ZNF24) expression by deubiquitination in a manner dependent on its catalytic1234567890();,:activity. YOD1 inhibition attenuated ZNF24 transcriptional repression of vascular endothelial growth factor A (VEGFA), therebypromoting VEGFA gene expression. Furthermore, ZNF24 was identified as a key mediator of YOD1 function. The expression of YOD1and ZNF24 was significantly downregulated in tumor tissues, with a strong correlation between them. Importantly, reduced YOD1and ZNF24 levels were strongly associated with poor clinical outcomes in ccRCC patients. Our results reveal the mechanism bywhich YOD1 regulates VEGFA transcription and suppresses tumorigenesis by deubiquitinating ZNF24, providing a therapeutictarget in ccRCC.Cell Death and Disease (2025) 16:334 ;
